Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) antibody
|Synonyms||Flk1, Ly73, Flk-1, Krd-1, VEGFR2, VEGFR-2, sVEGFR-2, 6130401C07, FLK1, CD309, VEGFR, Vegfr-2, MGC93590, KDR, FLK-1, flk-1, vegfr-2|
|Clonality||Monoclonal (AVAS 12alpha1)|
Alternatives Flow Cytometry (FACS), Western Blotting (WB), Immunohistochemistry (IHC)
|8 references available|
|Quantity||0.5 mg (0.5 mg/ml)|
|Price||Product not available in this region.|
|Immunogen||Mouse Flk1 and human IgG1 fusion protein|
The Avas 12alpha1 antibody reacts with fetal liver kinase 1 (Flk-1), a receptor protein tyrosine kinase closely related to CD117 (c-kit) and CD140a (PDGF Receptor alpha chain) of the immunoglobulin superfamily. Flk-1, also known as VEGF Receptor-2 (VEGF-R2), is a receptor for vascular endothelial growth factor (VEGF). It is expressed, at the mRNA and protein levels, on distinct sets of mesoderm during gastrulation and on endothelial cells in embryonic tissues. In vivo and in vitro studies indicate that Flk-1 is required for the embryonic development of vascular endothelial and hematopoietic cells.
Synonyms: VEGF-R2, Ly-73
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Sodium azide is a reversible inhibitor of oxidative metabolism, therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
|Application Notes||For immunohistochemistry application, we recommend to use purified Avas 12alpha1 mAb in our special formulation for immunohistochemistry.|
|Purification||Purified from tissue culture supernatant or ascites by affinity chromatography.|
|Buffer||Aqueous buffered solution.|
|Preservative||0.09% Sodium azide.|
|Storage||Store undiluted at 4° C.|
|Restrictions||For Research Use only|
Shalaby, Rossant, Yamaguchi et al.: "Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice." in: Nature, Vol. 376, Issue 6535, pp. 62-6, 1995 (PubMed).
Millauer, Wizigmann-Voos, Schnürch et al.: "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis." in: Cell, Vol. 72, Issue 6, pp. 835-46, 1993 (PubMed).
Quinn, Peters, De Vries et al.: "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, Issue 16, pp. 7533-7, 1993 (PubMed).
Shalaby, Ho, Stanford et al.: "A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis." in: Cell, Vol. 89, Issue 6, pp. 981-90, 1997 (PubMed).
Hanahan: "Signaling vascular morphogenesis and maintenance." in: Science (New York, N.Y.), Vol. 277, Issue 5322, pp. 48-50, 1997 (PubMed).
Kataoka, Takakura, Nishikawa et al.: "Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells." in: Development, growth & differentiation, Vol. 39, Issue 6, pp. 729-40, 1998 (PubMed).
Nishikawa, Nishikawa, Hirashima et al.: "Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages." in: Development (Cambridge, England), Vol. 125, Issue 9, pp. 1747-57, 1998 (PubMed).
Nishikawa, Nishikawa, Kawamoto et al.: "In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos." in: Immunity, Vol. 8, Issue 6, pp. 761-9, 1998 (PubMed).